3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
23
Lymphoma, Mantle-Cell
14
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
5
Waldenstrom Macroglobulinemia
4
Lymphoma, B-Cell
4
Lymphoma
4
Leukemia, B-Cell
4
Leukemia
3
Neoplasms
2
Melanoma
2
Leukemia, Prolymphocytic
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neurologic Manifestations
1
Myeloproliferative Disorders
1
Lymphoma, AIDS-Related
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Lymphoid
1
Leukemia, Hairy Cell
1
Hematologic Diseases
1
Graft vs Host Disease
1
Glioblastoma
1
Disease Progression
1
Central Nervous System Neoplasms
1
Cardiovascular Diseases
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Interventions
ibrutinib
1
Standard of Care
1
Lenalidomide
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neurologic Manifestations
×
ibrutinib
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled